Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 11/20 | 0.43 |
| ▸ | KCNK18 | Q7Z418 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 6/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.40 |
| ▸ | MERTK | Q12866 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749289 | 0.87 | PDK2 (0.50) | PDK2PDK1PDK3FGFR1DDR2 | |
| SCHEMBL25786733 | 0.80 | PDK2 (0.46) | PDK2KCNK18FGFR1DDR2 | |
| SCHEMBL20551821 | 0.77 | PDK2 (0.52) | PDK2FGFR1DDR2 | |
| SCHEMBL21764712 | 0.77 | PDK2 (0.50) | PDK2PDK1PDK3AXLTYRO3 | |
| SCHEMBL21765002 | 0.76 | ALDH1A1 (0.42) | FGFR1DDR2 | |
| SCHEMBL20553196 | 0.73 | GRIN1 (0.45) | PDK2FGFR1DDR2 | |
| SCHEMBL20552120 | 0.72 | YAP1 (0.46) | FGFR1DDR2 | |
| SCHEMBL20552230 | 0.70 | ALDH1A1 (0.45) | — | |
| SCHEMBL25786600 | 0.70 | KCNK18 (0.45) | KCNK18 | |
| SCHEMBL24504902 | 0.70 | KCNK18 (0.60) | KCNK18 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | PDK2 3742/4885KCNK18 3394/4885PDK1 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.